Skip to content
  • LinkedIn

The Business of Biofabrication

  • News
  • Perspectives
  • Learn

R.D. Solorzano

  • Tides Medical and UToledo Health Pioneer 3D Bioprinted Grafts for Chronic Wound Care
    July 3, 2025

    Tides Medical and UToledo Health Pioneer 3D Bioprinted Grafts for Chronic Wound Care

    R.D. Solorzano
  • Vertex’s Zimislecel Shows Early Promise for Insulin Independence
    July 2, 2025

    Vertex’s Zimislecel Shows Early Promise for Insulin Independence

    R.D. Solorzano
  • Biofabricated Organ Support: miroliverELAP’s First Human Treatment for Acute Liver Failure
    June 25, 2025

    Biofabricated Organ Support: miroliverELAP’s First Human Treatment for Acute Liver Failure

    R.D. Solorzano
  • OrganOx Secures $160M in Private Financing to Accelerate Organ Perfusion Technology Expansion
    May 8, 2025

    OrganOx Secures $160M in Private Financing to Accelerate Organ Perfusion Technology Expansion

    R.D. Solorzano
  • Collagen-Based 3D Bioprinting Offers Fully Perfusable Gel Based Organ-On-Chips
    May 6, 2025

    Collagen-Based 3D Bioprinting Offers Fully Perfusable Gel Based Organ-On-Chips

    R.D. Solorzano
  • Quris Technologies Demonstrates Liver-Driven Brain Toxicity in New Multi-Organ Model
    May 6, 2025

    Quris Technologies Demonstrates Liver-Driven Brain Toxicity in New Multi-Organ Model

    R.D. Solorzano
  • VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models
    May 6, 2025

    VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models

    R.D. Solorzano
  • Cellino and Karis Bio Partner to Advance Personalized iPSC Therapies for Peripheral Artery Disease
    April 27, 2025

    Cellino and Karis Bio Partner to Advance Personalized iPSC Therapies for Peripheral Artery Disease

    R.D. Solorzano
  • Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development
    April 27, 2025

    Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development

    R.D. Solorzano
  • Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology
    April 27, 2025

    Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology

    R.D. Solorzano
Previous Page
1 … 5 6 7 8 9 … 15
Next Page

Archives

To make sense of, stay update on, and learn about
the business of biofabrication

Subscribe

2024 All Rights Reserved

  • Subscribe Subscribed
    • The Business of Biofabrication
    • Already have a WordPress.com account? Log in now.
    • The Business of Biofabrication
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar